Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 28 Sep 2017 Results published in the Cancer.
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History